Skip to main content

Table 1 Patients’ characteristics

From: Prolonged direct hemoperfusion using a polymyxin B immobilized fiber cartridge provides sustained circulatory stabilization in patients with septic shock: a retrospective observational before-after study

 

PMX-DHP-2 h (n = 18)

PMX-DHP-12 h (n = 18)

P value

Age, years, median [IQR]

75 (64–84)

78 (60–83)

0.75

Male, number (%)

10 (56%)

7 (39%)

0.51

Body weight, kg, median [IQR]

60 (54–65)

58 (50–64)

0.45

APACHE II score at ICU admission, median [IQR]

25 (19–31)

21 (18–30)

0.40

Comorbidity

 Immunosuppression, number (%)

4 (22%)

4 (22%)

1.00

 Liver cirrhosis, number (%)

2 (11%)

0 (0%)

0.49

 Chronic dialysis, number (%)

0 (0%)

2 (11%)

0.49

 Home oxygenation therapy, number (%)

0 (0%)

1 (6%)

1.00

 Decompensate heart failure, number (%)

0 (0%)

1 (6%)

1.00

Source of admission to ICU

0.81

 Operating room after emergency surgery, number (%)

9 (50%)

11 (61%)

 

 Emergency department, number (%)

6 (33%)

5 (28%)

 

 Hospital ward, number (%)

3 (17%)

2 (11%)

 

Site of infection

 Abdomen, number (%)

11 (61%)

13 (72%)

0.72

 Thorax, number (%)

2 (11%)

1 (6%)

0.61

 Skin and soft tissue, number (%)

2 (11%)

1 (6%)

0.61

 Urinary tract, number (%)

1 (6%)

2 (11%)

0.61

 Others, number (%)

1 (6%)

2 (11%)

0.61

 Unknown, number (%)

1 (6%)

0 (0%)

1.00

Causative microorganisms

 Gram-negative rods, number (%)

4 (22%)

2 (11%)

0.66

 Gram-positive cocci, number (%)

4 (22%)

3 (17%)

1.00

 Gram-positive rods, number (%)

1 (6%)

0 (0%)

1.00

 Fungus, number (%)

0 (0%)

1 (6%)

1.00

 Mixed, number (%)

3 (17%)

7 (39%)

0.26

 Unknown, number (%)

6 (33%)

5 (28%)

1.00

Number of PMX-DHP session

1.00

 1 session, number (%)

6 (33%)

7 (39%)

 

 2 sessions, number (%)

12 (67%)

11 (61%)

 

Start of PMX-DHP from the onset of shock or ICU admission, h, median [IQR]a

3 (2–4)

4 (3–5)

0.09

Treatment in ICU

 Continuous renal replacement therapy, number (%)

11 (61%)

8 (44%)

0.51

 Mechanical ventilation, number (%)

18 (100%)

18 (100%)

1.00

 Low-dose steroid, number (%)

17 (94%)

15 (83%)

0.60

 Dose of fluid administration within 24 h after starting PMX-DHP, ml, median [IQR]

4285 [3587–7207]

4780 [3463–8220]

0.69

Laboratory testb

 White blood cell, 102/mcl, median [IQR]

77.0 (34.0–172.5)

88.2 (47.0–146.3)

1.00

 C reactive protein, mg/dl, median [IQR]

13.5 (4.6–22.5)

15.9 (9.2–24.1)

0.28

 Total bilirubin, mg/dl, median [IQR]

1.1 (0.8–2.1)

0.8 (0.6–1.8)

0.20

 Creatinine, mg/dl, median [IQR]

1.8 (1.1–2.5)

1.6 (1.2–2.5)

0.78

 PT-INR, median [IQR]

1.3 (1.2–2.0)

1.3 (1.2–1.8)

0.94

 Lactate, mmol/l, median [IQR]

7.0 (4.7–11.7)

4.6 (2.0–7.6)

0.03

  1. PMX-DHP-2 h polymyxin direct hemoperfusion for 2 h, PMX-DHP-12 h polymyxin direct hemoperfusion for 12 h, IQR interquartile range, APACHE II acute physiology and chronic health evaluation, ICU intensive care unit, PT-INR prothrombin time-international normalized ratio
  2. aOnset of shock was defined as the timing of inotropic score >10
  3. bLaboratory test was performed at the day of first PMX-DHP session